Biguanides and Thiazolidinediones Inhibit Stimulated Lipolysis in Human Adipocytes Through Activation of AMP-activated Protein Kinase

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2010 Jan 1

PMID 20043143

Citations 29

Authors

O Bourron

M Daval

I Hainault

E Hajduch

J M Servant

J F Gautier

P Ferre

F Foufelle

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: In rodent adipocytes, activated AMP-activated protein kinase reduces the lipolytic rate. As the hypoglycaemic drugs metformin and thiazolidinediones activate this enzyme in rodents, we tested the hypothesis that in addition to their known actions they could have an anti-lipolytic effect in human adipocytes.

Methods: Adipose tissue was obtained from individuals undergoing plastic surgery. Adipocytes were isolated and incubated with lipolytic agents (isoprenaline, atrial natriuretic peptide) and biguanides or thiazolidinediones. Lipolysis was quantified by the glycerol released in the medium. AMP-activated protein kinase activity and phosphorylation state were determined using standard procedures.

Results: In human adipocytes, isoprenaline and atrial natriuretic peptide stimulated the lipolytic rate three- to fourfold. Biguanides and thiazolidinediones activated AMP-activated protein kinase and inhibited lipolysis by 30-40%, at least in part by inhibiting hormone-sensitive lipase translocation to the lipid droplet. Inhibition of AMP-activated protein kinase by compound C precluded this inhibitory effect on lipolysis. Stimulation of lipolysis also induced an activation of AMP-activated protein kinase concomitant with a drop in ATP concentration.

Conclusions/interpretation: We show for the first time in human adipocytes that biguanides and thiazolidinediones activate AMP-activated protein kinase, thus counteracting lipolysis induced by lipolytic agents. In addition, beta-agonist- or ANP-stimulated lipolysis increases AMP-activated protein kinase activity. This is because of an increase in the AMP/ATP ratio, linked to activation of some of the released fatty acids into acyl-CoA. AMP-activated protein kinase activation could represent a physiological means of avoiding a deleterious drain of energy during lipolysis but could be used to restrain pharmacological release of fatty acids.

Citing Articles

Mitochondrial complex I inhibition triggers NAD-independent glucose oxidation via successive NADPH formation, "futile" fatty acid cycling, and FADH oxidation.

Abrosimov R, Baeken M, Hauf S, Wittig I, Hajieva P, Perrone C Geroscience. 2024; 46(4):3635-3658.

PMID: 38267672 PMC: 11226580. DOI: 10.1007/s11357-023-01059-y.

Development of a peptide drug restoring AMPK and adipose tissue functionality in cancer cachexia.

Ji H, Englmaier F, Morigny P, Giroud M, Grasle P, Brings S Mol Ther. 2023; 31(8):2408-2421.

PMID: 37408309 PMC: 10422018. DOI: 10.1016/j.ymthe.2023.06.020.

Cellular responses to 8-methyl nonanoic acid, a degradation by-product of dihydrocapsaicin, in 3T3-L1 adipocytes.

Wichai U, Keawsomnuk P, Thongin S, Mukthung C, Boonthip C, Pittayakhajonwut P BMC Complement Med Ther. 2023; 23(1):18.

PMID: 36681810 PMC: 9862568. DOI: 10.1186/s12906-023-03844-w.

Regulatory Effects of Metformin, an Antidiabetic Biguanide Drug, on the Metabolism of Primary Rat Adipocytes.

Szkudelski T, Konieczna K, Szkudelska K Molecules. 2022; 27(16).

PMID: 36014488 PMC: 9415039. DOI: 10.3390/molecules27165250.

The Current and Potential Therapeutic Use of Metformin-The Good Old Drug.

Drzewoski J, Hanefeld M Pharmaceuticals (Basel). 2021; 14(2).

PMID: 33562458 PMC: 7915435. DOI: 10.3390/ph14020122.

References

Miles J, Wooldridge D, Grellner W, Windsor S, Isley W, Klein S . Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy. Diabetes. 2003; 52(3):675-81. DOI: 10.2337/diabetes.52.3.675. View

Garton A, Campbell D, Carling D, Hardie D, Colbran R, Yeaman S . Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism. Eur J Biochem. 1989; 179(1):249-54. DOI: 10.1111/j.1432-1033.1989.tb14548.x. View

Boden G . Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997; 46(1):3-10. View

Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J . Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab. 2008; 19(4):130-7. DOI: 10.1016/j.tem.2007.11.006. View

Anthony N, Gaidhu M, Ceddia R . Regulation of visceral and subcutaneous adipocyte lipolysis by acute AICAR-induced AMPK activation. Obesity (Silver Spring). 2009; 17(7):1312-7. DOI: 10.1038/oby.2008.645. View

Duncan R, Ahmadian M, Jaworski K, Sarkadi-Nagy E, Sul H . Regulation of lipolysis in adipocytes. Annu Rev Nutr. 2007; 27:79-101. PMC: 2885771. DOI: 10.1146/annurev.nutr.27.061406.093734. View

Jansson P, Gudbjornsdottir H, Andersson O, Lonnroth P . The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM. Diabetes Care. 1996; 19(2):160-4. DOI: 10.2337/diacare.19.2.160. View

Tomoda H, Igarashi K, Omura S . Inhibition of acyl-CoA synthetase by triacsins. Biochim Biophys Acta. 1987; 921(3):595-8. View

Boon H, Bosselaar M, Praet S, Blaak E, Saris W, Wagenmakers A . Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients. Diabetologia. 2008; 51(10):1893-900. DOI: 10.1007/s00125-008-1108-7. View

10.

Ye J, Dzamko N, Hoy A, Iglesias M, Kemp B, Kraegen E . Rosiglitazone treatment enhances acute AMP-activated protein kinase-mediated muscle and adipose tissue glucose uptake in high-fat-fed rats. Diabetes. 2006; 55(10):2797-804. DOI: 10.2337/db05-1315. View

11.

Daval M, Diot-Dupuy F, Bazin R, Hainault I, Viollet B, Vaulont S . Anti-lipolytic action of AMP-activated protein kinase in rodent adipocytes. J Biol Chem. 2005; 280(26):25250-7. DOI: 10.1074/jbc.M414222200. View

12.

Garton A, Yeaman S . Identification and role of the basal phosphorylation site on hormone-sensitive lipase. Eur J Biochem. 1990; 191(1):245-50. DOI: 10.1111/j.1432-1033.1990.tb19116.x. View

13.

Fryer L, Carling D . The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem. 2002; 277(28):25226-32. DOI: 10.1074/jbc.M202489200. View

14.

Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E . Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes. 1994; 43(7):920-8. DOI: 10.2337/diab.43.7.920. View

15.

Foretz M, Carling D, Guichard C, Ferre P, Foufelle F . AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J Biol Chem. 1998; 273(24):14767-71. DOI: 10.1074/jbc.273.24.14767. View

16.

Su C, Sztalryd C, Contreras J, Holm C, Kimmel A, Londos C . Mutational analysis of the hormone-sensitive lipase translocation reaction in adipocytes. J Biol Chem. 2003; 278(44):43615-9. DOI: 10.1074/jbc.M301809200. View

17.

Porta V, Schramm S, Kano E, Koono E, Armando Y, Fukuda K . HPLC-UV determination of metformin in human plasma for application in pharmacokinetics and bioequivalence studies. J Pharm Biomed Anal. 2007; 46(1):143-7. DOI: 10.1016/j.jpba.2007.10.007. View

18.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J . Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001; 108(8):1167-74. PMC: 209533. DOI: 10.1172/JCI13505. View

19.

Moule S, Denton R . The activation of p38 MAPK by the beta-adrenergic agonist isoproterenol in rat epididymal fat cells. FEBS Lett. 1998; 439(3):287-90. DOI: 10.1016/s0014-5793(98)01392-1. View

20.

Rodbell M . METABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM AND LIPOLYSIS. J Biol Chem. 1964; 239:375-80. View